Guo Qi, Chang Yajie, Li Jingjie, Zhou Chuanchuan, Huang Rui, Yang Xing, Liu Guihua, Liang Xiaoyan
Center of Reproductive Medicine, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
Front Bioeng Biotechnol. 2022 Apr 25;10:735465. doi: 10.3389/fbioe.2022.735465. eCollection 2022.
Stem cell-based therapy plays a pivotal role in the regeneration of damaged endometrium. Previous studies have demonstrated the therapeutic potential of bone marrow mesenchymal stem cells (BMSCs) through diverse administration ways. However, the homing, survival, and differentiation potential of these differently administered BMSCs are poorly defined, and the best route of administration is not well-defined. Herein, we aim to compare the engraftment, retaining time, and therapeutic efficiency of differently administered BMSCs. To achieve this, GFP/Luc-labeled BMSCs administered in two modes were assessed in a thin endometrium rat model: either into the damaged horns directly or through the ipsilateral iliac artery. The retaining time and hemi-quantitative distribution were evaluated by bioluminescence imaging and immunohistological analysis. Locally administered BMSCs were strongly detected in the abdomen at the first 4 days post treatment but underwent a rapid decrease in luminescent signal afterward and were rarely found 28 days after treatment. In contrast, the retaining time of BMSCs injected through the iliac artery was longer, reflected by more GFP-positive cells detected in the uterine section 28 days post treatment. Differentiation toward endometrial stromal cells was observed. Both routes of administration contributed to the restoration of the damaged endometrium, showing a comparable increase in the endometrial thickness and a decrease in fibrosis. However, more importantly, higher expression of LIF and VEGF, better recruitment, and longer retainment were found in the intra-arterial administration, contributing to the establishment of the optimal administration mode in clinical practice.
基于干细胞的疗法在受损子宫内膜的再生中起着关键作用。先前的研究已经通过多种给药方式证明了骨髓间充质干细胞(BMSCs)的治疗潜力。然而,这些不同给药方式的BMSCs的归巢、存活和分化潜力尚未明确界定,最佳给药途径也不明确。在此,我们旨在比较不同给药方式的BMSCs的植入、保留时间和治疗效率。为了实现这一目标,在薄型子宫内膜大鼠模型中评估了两种给药模式下的绿色荧光蛋白/荧光素酶标记的BMSCs:直接注入受损子宫角或通过同侧髂动脉给药。通过生物发光成像和免疫组织学分析评估保留时间和半定量分布。局部给药的BMSCs在治疗后的前4天在腹部被强烈检测到,但随后发光信号迅速下降,在治疗后28天很少被发现。相比之下,通过髂动脉注射的BMSCs的保留时间更长,治疗后28天在子宫切片中检测到更多的绿色荧光蛋白阳性细胞。观察到向子宫内膜基质细胞的分化。两种给药途径都有助于受损子宫内膜的修复,子宫内膜厚度增加和纤维化减少的情况相当。然而,更重要的是,动脉内给药中发现白血病抑制因子(LIF)和血管内皮生长因子(VEGF)的表达更高、募集更好且保留时间更长,这有助于在临床实践中建立最佳给药模式。